Mometaxon (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometaxon, is a potent corticosteroid presented as a topical formulation for skin application. It is used to manage inflammatory skin disorders such as psoriasis, atopic dermatitis, seborrheic dermatitis, contact dermatitis and other related conditions in both adults and children under medical supervision.

GNH USA supplies Mometaxon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards. The company ensures product quality, traceability and compliance with Good Distribution Practice throughout the supply chain.

Mometasone furoate is a topical corticosteroid that reduces inflammation in various dermatoses.

- Psoriasis: decreases plaque thickness, erythema and scaling. - Atopic dermatitis (eczema): relieves itching, redness and inflammation. - Seborrheic dermatitis: controls scaling and facial redness. - Contact dermatitis: diminishes allergic skin reactions. - Nummular eczema: reduces lesion size and pruritus.

Mometasone furoate may cause local and systemic adverse reactions.

Common Side Effects: - Skin irritation or burning sensation at the application site. - Pruritus or mild itching. - Dryness or peeling of the treated skin. - Acneiform eruptions or folliculitis.

Serious or Rare Side Effects: - Hypothalamic‑pituitary‑adrenal (HPA) axis suppression with systemic effects. - Severe allergic reactions such as angioedema or urticaria. - Skin atrophy, telangiectasia or striae formation. - Secondary bacterial, fungal or viral skin infections.

Before using Mometaxon, consider the following precautions. - Assess severity: limit use to mild‑moderate conditions and avoid extensive body surface coverage. - Use lowest potency: apply the smallest effective amount for the shortest duration. - Avoid prolonged use: discontinue after recommended treatment period to prevent skin atrophy. - Do not apply to infected or ulcerated skin without medical advice. - Avoid occlusion: do not cover treated area with airtight dressings unless directed. - Store at room temperature: keep in the original container, protect from moisture and light.

Mometaxon may interact with other agents; monitor accordingly.

Major Interactions (Avoid): - Systemic corticosteroids: increased risk of HPA‑axis suppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise systemic absorption. - Antifungal agents (e.g., azoles): potential additive immunosuppression. - Live vaccines: reduced vaccine efficacy due to immunosuppression.

Moderate Interactions (Monitor Closely): - Antidiabetic drugs: possible hyperglycaemia. - Antihistamines: may mask local irritation. - Phototherapy: heightened skin sensitivity. - Topical antibiotics: risk of combined skin irritation. - Systemic immunosuppressants: additive effect on immune function.